Article
Fort Lauderdale, FL-The investigational fourth-generation fluoroquinolones moxifloxacin and gatifloxacin show prom-ising potential for providing broad- spectrum coverage against important gram-negative and gram-positive ocular pathogens, according to results of in vitro susceptibility testing presented at the annual meeting of the Association for Research in Vision and Ophthalmology.